These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27984399)

  • 21. Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; López-Díaz J; Bastón Rey I; Domínguez-Muñoz JE
    Rev Esp Enferm Dig; 2022 Jan; 114(1):10-15. PubMed ID: 33486959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Garcia-Planella E; Mañosa M; Chaparro M; Beltrán B; Barreiro-de-Acosta M; Gordillo J; Ricart E; Bermejo F; García-Sánchez V; Piqueras M; Llaó J; Gisbert JP; Cabré E; Domènech E;
    Scand J Gastroenterol; 2018 Feb; 53(2):152-157. PubMed ID: 29189092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
    Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
    Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis.
    Lasson A; Simrén M; Stotzer PO; Isaksson S; Ohman L; Strid H
    Inflamm Bowel Dis; 2013 Mar; 19(3):576-81. PubMed ID: 23377170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
    Yang Z; Clark N; Park KT
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.
    Henderson P; Casey A; Lawrence SJ; Kennedy NA; Kingstone K; Rogers P; Gillett PM; Wilson DC
    Am J Gastroenterol; 2012 Jun; 107(6):941-9. PubMed ID: 22370604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can calprotectin predict relapse risk in inflammatory bowel disease?
    D'Incà R; Dal Pont E; Di Leo V; Benazzato L; Martinato M; Lamboglia F; Oliva L; Sturniolo GC
    Am J Gastroenterol; 2008 Aug; 103(8):2007-14. PubMed ID: 18802997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy.
    Koulaouzidis A; Douglas S; Rogers MA; Arnott ID; Plevris JN
    Scand J Gastroenterol; 2011 May; 46(5):561-6. PubMed ID: 21269246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.
    Yamamoto T; Shiraki M; Bamba T; Umegae S; Matsumoto K
    Int J Colorectal Dis; 2014 Apr; 29(4):485-91. PubMed ID: 24343276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
    World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
    De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
    Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
    Rokkas T; Portincasa P; Koutroubakis IE
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.
    Brooks AJ; Sebastian S; Cross SS; Robinson K; Warren L; Wright A; Marsh AM; Tsai H; Majeed F; McAlindon ME; Preston C; Hamlin PJ; Lobo AJ
    J Crohns Colitis; 2017 Dec; 11(12):1456-1462. PubMed ID: 25311864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation Between Calprotectin and Modified Rutgeerts Score.
    Lopes S; Andrade P; Afonso J; Rodrigues-Pinto E; Dias CC; Macedo G; Magro F
    Inflamm Bowel Dis; 2016 Sep; 22(9):2173-81. PubMed ID: 27482974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study.
    Shimoyama T; Yamamoto T; Umegae S; Matsumoto K
    BMC Gastroenterol; 2018 Aug; 18(1):120. PubMed ID: 30068300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
    Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.